Survival after hypofractionation in glioblastoma: a systematic review and meta-analysis.
glioblastoma
hypofractionation
meta-analysis, review
methodology
radiotherapy
survival outcome
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
08 Jun 2020
08 Jun 2020
Historique:
received:
22
04
2020
accepted:
25
05
2020
entrez:
10
6
2020
pubmed:
10
6
2020
medline:
13
4
2021
Statut:
epublish
Résumé
Glioblastoma multiforme (GBM) has a poor prognosis despite a multi modal treatment that includes normofractionated radiotherapy. So, various hypofractionated alternatives to normofractionated RT have been tested to improve such prognosis. There is need of systematic review and meta-analysis to analyse the literature properly and maybe generalised the use of hypofractionation. The aim of this study was first, to perform a meta-analysis of all controlled trials testing the impact of hypofractionation on survival without age restriction and secondly, to analyse data from all non-comparative trials testing the impact of hypofractionation, radiosurgery and hypofractionated stereotactic RT in first line. We searched Medline, Embase and Cochrane databases to identify all publications testing the impact of hypofractionation in glioblastoma between 1985 and March 2020. Combined hazard ratio from comparative studies was calculated for overall survival. The impact of study design, age and use of adjuvant temozolomide was explored by stratification. Meta-regressions were performed to determine the impact of prognostic factors. 2283 publications were identified. Eleven comparative trials were included. No impact on overall survival was evidenced (HR: 1.07, 95%CI: 0.89-1.28) without age restriction. The analysis of non-comparative literature revealed heterogeneous outcomes with limited quality of reporting. Concurrent chemotherapy, completion of surgery, immobilization device, isodose of prescription, and prescribed dose (depending on tumour volume) were poorly described. However, results on survival are encouraging and were correlated with the percentage of resected patients and with patients age but not with median dose. Because few trials were randomized and because the limited quality of reporting, it is difficult to define the place of hypofactionation in glioblastoma. In first line, hypofractionation resulted in comparable survival outcome with the benefit of a shortened duration. The method used to assess hypofractionation needs to be improved.
Sections du résumé
BACKGROUND
BACKGROUND
Glioblastoma multiforme (GBM) has a poor prognosis despite a multi modal treatment that includes normofractionated radiotherapy. So, various hypofractionated alternatives to normofractionated RT have been tested to improve such prognosis. There is need of systematic review and meta-analysis to analyse the literature properly and maybe generalised the use of hypofractionation. The aim of this study was first, to perform a meta-analysis of all controlled trials testing the impact of hypofractionation on survival without age restriction and secondly, to analyse data from all non-comparative trials testing the impact of hypofractionation, radiosurgery and hypofractionated stereotactic RT in first line.
MATERIALS/METHODS
METHODS
We searched Medline, Embase and Cochrane databases to identify all publications testing the impact of hypofractionation in glioblastoma between 1985 and March 2020. Combined hazard ratio from comparative studies was calculated for overall survival. The impact of study design, age and use of adjuvant temozolomide was explored by stratification. Meta-regressions were performed to determine the impact of prognostic factors.
RESULTS
RESULTS
2283 publications were identified. Eleven comparative trials were included. No impact on overall survival was evidenced (HR: 1.07, 95%CI: 0.89-1.28) without age restriction. The analysis of non-comparative literature revealed heterogeneous outcomes with limited quality of reporting. Concurrent chemotherapy, completion of surgery, immobilization device, isodose of prescription, and prescribed dose (depending on tumour volume) were poorly described. However, results on survival are encouraging and were correlated with the percentage of resected patients and with patients age but not with median dose.
CONCLUSIONS
CONCLUSIONS
Because few trials were randomized and because the limited quality of reporting, it is difficult to define the place of hypofactionation in glioblastoma. In first line, hypofractionation resulted in comparable survival outcome with the benefit of a shortened duration. The method used to assess hypofractionation needs to be improved.
Identifiants
pubmed: 32513205
doi: 10.1186/s13014-020-01584-6
pii: 10.1186/s13014-020-01584-6
pmc: PMC7278121
doi:
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
145Références
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
Stereotact Funct Neurosurg. 1993;61 Suppl 1:59-64
pubmed: 8115757
Radiother Oncol. 2000 Feb;54(2):143-8
pubmed: 10699477
Radiat Oncol Investig. 1998;6(4):175-81
pubmed: 9727877
JAMA. 1996 Aug 28;276(8):637-9
pubmed: 8773637
J Neurooncol. 2009 Sep;94(3):409-18
pubmed: 19330482
Radiother Oncol. 2018 Apr;127(1):108-113
pubmed: 29291951
Int J Radiat Oncol Biol Phys. 2014 Mar 15;88(4):793-800
pubmed: 24495592
J Neurosurg. 1995 Apr;82(4):530-5
pubmed: 7897511
Neurosurgery. 2005 Oct;57(4):684-92; discussion 684-92
pubmed: 16239880
Neurosurg Rev. 2009 Oct;32(4):417-24
pubmed: 19633875
Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):655-60
pubmed: 22483738
J Neurooncol. 2015 Nov;125(2):359-67
pubmed: 26423801
Can J Neurol Sci. 1997 May;24(2):110-5
pubmed: 9164686
Chin Med Sci J. 2004 Jun;19(2):105-10
pubmed: 15250245
Technol Cancer Res Treat. 2008 Jun;7(3):249-55
pubmed: 18473497
Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):721-6
pubmed: 14967426
Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):1066-74
pubmed: 20932651
Clin Cancer Res. 2014 Oct 1;20(19):5023-31
pubmed: 25107913
Radiother Oncol. 1994 Nov;33(2):113-6
pubmed: 7535939
Radiat Oncol. 2017 Dec 6;12(1):197
pubmed: 29212499
J Neurooncol. 2019 Jun;143(2):177-185
pubmed: 30919157
Neurosurgery. 2002 Jan;50(1):41-6; discussion 46-7
pubmed: 11844233
Lancet Oncol. 2012 Sep;13(9):916-26
pubmed: 22877848
Radiother Oncol. 2010 Dec;97(3):377-81
pubmed: 20855119
Oncotarget. 2017 Jun 28;8(40):67696-67708
pubmed: 28978064
Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2S):E131-E132
pubmed: 27673859
Radiat Oncol. 2019 Jun 13;14(1):104
pubmed: 31196126
J Neurooncol. 2006 May;78(1):91-7
pubmed: 16314936
J Neurooncol. 2015 Mar;122(1):135-43
pubmed: 25524817
Radiother Oncol. 2003 May;67(2):183-90
pubmed: 12812849
J Geriatr Oncol. 2020 May;11(4):680-687
pubmed: 31521589
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
Int J Radiat Oncol Biol Phys. 2006 Aug 1;65(5):1422-8
pubmed: 16750317
Br J Radiol. 2012 Sep;85(1017):e770-81
pubmed: 22919020
Radiol Med. 2018 Jan;123(1):48-62
pubmed: 28879459
Int J Radiat Oncol Biol Phys. 1995 Sep 30;33(2):461-8
pubmed: 7673034
J Neurosurg. 2015 Apr;122(4):757-65
pubmed: 25594327
J Neurooncol. 2018 Oct;140(1):75-82
pubmed: 29936695
J Clin Oncol. 2006 Mar 1;24(7):1136-44
pubmed: 16505433
Tumori. 2019 Feb;105(1):47-54
pubmed: 30131010
J Neurooncol. 2019 Jul;143(3):447-455
pubmed: 31054101
Technol Cancer Res Treat. 2004 Feb;3(1):41-9
pubmed: 14750892
J Neurosurg. 1999 Jan;90(1):72-7
pubmed: 10413158
J Neurooncol. 2002 Apr;57(2):151-60
pubmed: 12125977
Int J Radiat Oncol Biol Phys. 1995 Apr 30;32(1):205-10
pubmed: 7721617
J Clin Oncol. 1992 Sep;10(9):1379-85
pubmed: 1325539
Radiother Oncol. 2003 Jul;68(1):23-6
pubmed: 12885448
Perm J. 2015 Winter;19(1):15-20
pubmed: 25663202
Radiat Oncol. 2009 Mar 17;4:11
pubmed: 19292912
Int J Radiat Oncol Biol Phys. 1996 Dec 1;36(5):1045-53
pubmed: 8985026
Int J Radiat Oncol Biol Phys. 2015 Jan 1;91(1):109-15
pubmed: 25442339
PLoS One. 2019 Jun 6;14(6):e0217881
pubmed: 31170245
CNS Oncol. 2019 Dec 1;8(4):CNS47
pubmed: 31818127
J Clin Oncol. 2004 May 1;22(9):1583-8
pubmed: 15051755
Int J Radiat Oncol Biol Phys. 2015 Jun 1;92(2):384-9
pubmed: 25841623
J Neurooncol. 2018 Jan;136(2):307-315
pubmed: 29090416
Int J Radiat Oncol Biol Phys. 1994 Oct 15;30(3):541-9
pubmed: 7928484
Int J Radiat Oncol Biol Phys. 2004 Nov 1;60(3):853-60
pubmed: 15465203
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120